Abbott (NYSE:ABT) announced today that a new real-world meta-analysis provided positive data for its FreeStyle Libre system. The analysis of 75 real-world observational studies of the FreeStyle Libre continuous glucose monitoring (CGM) system demonstrated significant reductions in glycated hemoglobin (HbA1c) sustained for up to 24 months in adults with both type 1 and type 2 […]
Study results show improved time in range with Diabeloop automated insulin delivery system
Diabeloop announced today that study data support the use of its DBLG1 hybrid closed-loop automated insulin delivery system. Paris-based Diabeloop’s real-life German cohort data, presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona, show a constant improvement in time in range (70-180 mg/dL) combined with a significant reduction of hypoglycemia. According […]
Study supports use of PharmaJet’s needle-free vaccine delivery systems
PharmaJet announced today that study data demonstrated increased immunogenicity when using its needle-free delivery system. Golden, Colorado-based PharmaJet presented the research results for the needle-free vaccine injection technology last week at the World Vaccine Congress. PharmaJet’s needle-free systems have been incorporated into clinical studies for multiple RNA and DNA vaccine and therapeutic development programs thanks […]
Study shows sustained improvements with Medtronic’s MiniMed 780G with Guardian 4
Medtronic (NYSE:MDT) announced today that the extended study phase of its MiniMed 780G insulin pump system produced positive data. Fridley, Minnesota-based Medtronic presented new data from the study of MiniMed 780G with the no-calibration, non-adjunctive Guardian 4 sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Barcelona. Data demonstrated sustained improvements in […]
Data shows improved outcomes with DarioHealth’s chronic condition management platform
DarioHealth (Nasdaq:DRIO) today announced real-world study data on the impact of managing diabetes and weight on a single digital platform. New York-based DarioHealth presented the published retrospective, real-world study observing its digital therapeutics platform at the Advanced Technologies and Treatments for Diabetes (ATTD) Conference in Barcelona. Get the full story at our sister site, MassDevice.
Glooko adds former Eli Lilly exec to its board of directors
Diabetes management technology developer Glooko announced today that it appointed Alfonso “Chito” Zulueta to its board of directors. Zulueta joins Palo Alto, California-based Glooko’s board having spent more than 30 years with Eli Lilly and Company, serving as a senior executive across an array of global business and commercial units. According to a news release, […]
Abbott, Camdiab, Ypsomed forge partnership for automated insulin delivery
Abbott (NYSE:ABT) announced today that it partnered with CamDiab and Ypsomed (SWX:YPSN) to produce an integrated automated insulin delivery (AID) system. The companies announced the partnership at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain. It seeks to develop and commercialize the integrated AID system with an initial focus centered around […]
Insulet announces positive study data for Omnipod 5 for type 1, type 2 diabetes
Insulet (Nasdaq:PODD) today unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes. Acton, Massachusetts-based Insulet presented results from studies as well as user experience data for both type 1 and type 2 diabetes at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, […]
Sweetch adds American Diabetes Association exec to its advisory board
Chronic condition therapeutic developer Sweetch announced today that Dr. Robert A. Gabbay has joined the company as an advisor. Gabbay currently serves as the chief scientific and medical officer at the American Diabetes Association, leading the organization’s efforts to drive discovery in diabetes research, care and prevention. He also serves as an associate professor of […]
Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation
Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand. Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in […]
